From the Department of Dermatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. The authors have no relevant financial interest in this article.
Patch tests are considered safe but adverse reactions have been reported.
A case of acute generalized exanthematous pustulosis (AGEP) provoked by a patch test with acetaminophen is described. Of special interest are the negative patch test results obtained with the offending drug. The case is discussed against the background of the putative mechanisms of AGEP and the reported systemic reactions to patch testing for AGEP.
To our knowledge, this is the first report in the English-language literature of a generalized AGEP-like reaction caused by patch tests carried out to determine the drug eliciting AGEP.
PATCH TESTING is becoming an accepted tool in the differential diagnosis of acute generalized exanthematous pustulosis (AGEP) and the search for the causative agent. Although it is considered safe, adverse reactions have to be anticipated. We report a case of acetaminophen-induced AGEP provoked by a patch test. To our knowledge, this is the first report in the English literature of a systemic AGEP reaction following patch testing.
A 23-year-old woman was admitted to the hospital following exacerbation of a pruritic rash. Three days earlier she had been treated for nasal discharge with Coldex (Teva Pharmaceuticals, Israel), a medication containing acetaminophen, caffeine, phenylephrine, and chlorpheniramine. One day later she developed erythema and itching on the buttocks and groin, and the following day she was given acetaminophen for the persistent itching. She had developed a similar rash 3 years earlier. Otherwise, she was in good general health, took no medications or nutritional supplements, and did not have a history of psoriasis.
The results of a physical examination on admission were normal, with the exception of a bilateral erythematous, maculopapular rash affecting the trunk and proximal limbs, and of numerous nonfollicular pustules on an erythematous base—mainly on the groin, buttocks, and the antecubital and popliteal fossae. Her body temperature was 37.6°C.
Laboratory investigations showed a total white cell count of 17 700/µL, and the differential count showed 71% neutrophils and 6% eosinophils. Blood, urine, throat, and pustule cultures produced negative results, as did a viral serologic test. Chest radiograph results were also normal. A skin biopsy of a pustule on an erythematous base taken from the groin showed neutrophil-containing spongiform subcorneal pustules as well as perivascular infiltrates with neutrophils and eosinophils. The results of direct and indirect lesional immunofluorescence were negative. Upon admission to our department the suspected offending drug was discontinued, and the eruption resolved within 5 days without any medications.
Six months later the patient received patch tests with the ingredients of Coldex, ie, 1% and 10% acetaminophen in petrolatum, 1% and 10% phenylephrine in petrolatum, 1.5% phenylephrine in distilled water, 1% chlorpheniramine in both petrolatum and distilled water, and 0.5% caffeine in petrolatum. On day 2 the reading for the patch containing 1% acetaminophen was 3 tiny papules and the other readings were negative. On days 4 and 7 all readings were negative. On day 7, however, the patient developed a symmetric vesiculopustular eruption on the trunk and extremities. Histologic examination of a skin biopsy sample from one of these lesions revealed papillary edema and perivascular infiltrates with neutrophils and eosinophils. The eruption resolved after 1 week. A patch test 1 month later using only 1% and 10% acetaminophen in petrolatum provoked no reaction on days 2, 4, and 7. But on day 6, the patient developed a rash similar to the one that erupted on day 7 of the previous test. That rash had resolved spontaneously by day 10. Separate patch tests with each of the other ingredients of the suspected drug were negative.
Baker and Rayan1 coined exanthemic pustular psoriasis in 1968 to describe and name the condition, and in 1980 Beylot et al2 proposed pustuloses exanthématiques aiguës généralisées. The latter prevailed, and the condition is now referred to in English as acute generalized exanthematous pustulosis (AGEP).
Drugs trigger off this relatively rare phenomenon in 90% of cases, especially antibiotics and particularly βlactams.3 Other etiologic agents are mercury; viruses, including parvovirus B19, coxsackievirus B4 and coxsackievirus A9, Epstein-Barr virus, cytomegalovirus, hepatitis B virus; and Mycoplasma pneumoniae3- 7 (Table 1).
Several pathogenic mechanisms of AGEP have been proposed. Britschgi et al8 suggested the involvement of T cells, which is evidenced by positive patch tests and lymphocyte transformation tests. The cell-bound drug elicits a drug-specific CD4 and CD8 immune reaction producing interleukin 8 and interleukin 5. They, in turn, cause aggregation of neutrophils and eosinophils,8 in addition to their cytotoxic effect on basal cells.9 Based on the positive patch test results, Moreau et al10 proposed that AGEP is a delayed type of hypersensitivity reaction. Another possible mechanism is the production of antigen-antibody complexes induced by an infection or drug that activates the complement system, which in turn causes neutrophil chemotaxis.11,12
Definitive confirmation of a certain drug as the cause of AGEP theoretically can be obtained by rechallenging the patient with the suspected drug. In view of the possible recurrence of the full-fledged eruption, patch test can serve as a substitute mimicking AGEP both clinically and histologically at the patch test site only. The rationale for using patch tests in AGEP is founded mainly on the pathogenesis of AGEP, which, as mentioned above, includes T-cell involvement and a delayed-type hypersensitivity reaction. Wolkenstein et al13 reported positive patch tests in 7 of 14 patients with AGEP13; Watsky14 suggested that rates of positive patch tests may be even higher, but noted that this may reflect a publication bias. Table 1 summarizes the drugs reported to provoke a positive AGEP patch test.15
Although the patch test reaction in most AGEP cases is limited to the test site, there are a few reports of reactions spreading beyond this site, most of them attributed to diltiazem hydrochloride. Nishimura et al16 reported a generalized AGEP-like reaction caused by a patch test with diltiazem; Vincente-Calleja et al17 described the appearance of a diffuse pruritic eruption on the neck, abdomen, and patch test area—which resolved in a few days—after a positive patch test with diltiazem; and Wakelin and James18 reported a positive patch test with diltiazem accompanied by a mild eczematous reaction on both forearms.
Despite the value of patch tests in the diagnosis of AGEP and the determination of the condition's etiology, the method has drawbacks. There is no standardization for the tests whose specificity and sensitivity are yet to be determined. It is well known that sometimes, including in AGEP cases, a patch test can fail to provoke a reaction in a person who is sensitive to the substance tested. There are several reasons for these negative results, especially when the test is performed with specially prepared materials rather than standard test patches. Among the more common reasons are the different mechanisms of action of the drugs being tested, excessively low drug concentration, insufficient amount of drug applied, inappropriate vehicle, degradation of the substance, and UV irradiation of the patch test site.
Our patient experienced a cutaneous reaction after taking a medication containing acetaminophen, caffeine, phenylephrine, and chlorpheniramine. Another administration of acetaminophen severely exacerbated the cutaneous reaction, which resolved a few days after the medication was discontinued. Patch tests with the alleged culprits were deemed negative despite the appearance of 3 tiny papules at the site of application of 1% acetaminophen, because the papules lasted only 48 hours. A test with a 10-fold-higher concentration of acetaminophen was also negative, and the results of the first test with 1% acetaminophen could not be reproduced at a later time. However, with the initial patch test containing all the ingredients of the suspected drug as well as the subsequent one containing acetaminophen alone, the patient experienced a generalized cutaneous reaction consisting of symmetric vesiculopustular lesions on the trunk and extremities that resolved within a few days. On histologic examination, a skin biopsy specimen of one of the vesiculopustules exhibited some of the histological features of AGEP.
Although the patch test results were negative in our case, the reproducible generalized AGEP-like reaction following patch testing with acetaminophen, together with the histological findings, suggest an acetaminophen-induced AGEP in our patient. As mentioned above, acetaminophen has already been reported as a possible cause of AGEP.
In view of the short interval (24 hours) between administration of the offending drug and appearance of the eruption, and the similarity of that rash and the rash she experienced 3 years earlier, it can also be assumed that acetaminophen caused the earlier AGEP as well.
To our knowledge, this is the first report in the English literature of a generalized AGEP-like reaction caused by patch tests carried out to determine the culprit drug in a case of AGEP. Of special interest are the negative patch test results with the offending drug.
Corresponding author and reprints: Sarah Brenner, MD, Department of Dermatology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv, 64239 Israel (e-mail: firstname.lastname@example.org).
Accepted for publication January 28, 2003.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Dermatology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 35
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.